HRP20210680T1 - POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL - Google Patents
POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL Download PDFInfo
- Publication number
- HRP20210680T1 HRP20210680T1 HRP20210680TT HRP20210680T HRP20210680T1 HR P20210680 T1 HRP20210680 T1 HR P20210680T1 HR P20210680T T HRP20210680T T HR P20210680TT HR P20210680 T HRP20210680 T HR P20210680T HR P20210680 T1 HRP20210680 T1 HR P20210680T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 35
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 201000010374 Down Syndrome Diseases 0.000 claims 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 210000001124 body fluid Anatomy 0.000 claims 6
- 239000010839 body fluid Substances 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 230000009529 traumatic brain injury Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000004558 lewy body Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010002023 Amyloidoses Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
Claims (20)
1. Protutijelo ili njegov ulomak koji veže antigen, naznačeno time što sadrži:
(a) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 12; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 16;
(b) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 9; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 15;
(c) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 10; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 15;
(d) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 11; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 15;
(e) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 12; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 15;
(f) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 9; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 16
(g) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 10; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 16; ili
(h) varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 11; i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 16.
2. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1, naznačeno time što protutijelo ili njegov ulomak koji veže antigen sadrži konstantnu regiju IgG teškog lanca.
3. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time što se koristi u terapiji.
4. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time što je za upotrebu u liječenju i/ili profilaksi Alzheimerove bolesti i drugih poremećaja povezanih s agregacijom Aβ proteina, kao što je traumatska ozljeda mozga (TBI), demencija s Lewyjevim tjelešcima (LBD), Downov sindrom (DS), amiotrofična lateralna skleroza (ALS), frontotemporalna demencija, tauopatije, sistemske amiloidoze, ateroskleroza i Parkinsonova bolest s demencijom (PDD).
5. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time što se koristi u postupku smanjenja količine Aβ protofibrila kod subjekta, koji obuhvaća davanje navedenom subjektu terapeutski učinkovite količine protutijela ili njegovog ulomka koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2.
6. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time što se koristi u postupku za mjerenje količine Aβ protofibrila i/ili agregiranog Aβ proteina kod osobe, koji uključuje dovođenje u kontakt tkiva ili tjelesne tekućine osobe, in vivo, s protutijelom ili njegovim ulomkom koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2 i mjerenje količine navedenog protutijela ili njegovog ulomaka koji veže antigen vezane na navedene Aβ protofibrile i/ili agregirani Aβ protein.
7. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2 naznačeno time što se koristi u postupku za dijagnozu Alzheimerove bolesti kod osoba koje imaju ili su u opasnosti od razvoja bolesti, koji uključuje dovođenje u kontakt tkiva ili tjelesne tekućine osobe, in vivo, s protutijelom ili njegovim ulomkom koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, ili njegovim ulomkom, te mjerenje količine navedenog protutijela vezane za agregirani Aβ protein.
8. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2 naznačeno time što se koristi u postupku za dijagnozu traumatske ozljede mozga (TBI), demencije s Lewyjevim tjelešcima (LBD), Downovog sindroma (DS), amiotrofične lateralne skleroze (ALS), frontotemporalne demencije, tauopatija, sistemske amiloidoze, ateroskleroze i Parkinsonove bolesti s demencijom (PDD) kod osoba koje imaju ili su u opasnosti od razvoja bilo koje od navedenih bolesti, koji uključuje dovođenje u kontakt tkiva ili tjelesne tekućine osobe, in vivo, s protutijelom ili njegovim ulomkom koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, te mjerenje količine navedenog protutijela ili njegovog ulomaka koji veže antigen vezane za agregirani Aβ protein.
9. Farmaceutski pripravak naznačen time što sadrži protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, zajedno s farmaceutski prihvatljivim pomoćnim sredstvom i/ili razrjeđivačima.
10. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time što je za veterinarsku upotrebu.
11. Protutijelo ili njegov ulomak koji veže antigen koje ima afinitet prema Aβ protofibrilima, naznačeno time što protutijelo ili njegov ulomak koji veže antigen sadrži varijabilni laki lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 12 i varijabilni teški lanac koji sadrži aminokiselinsku sekvencu kako je navedeno u SEQ ID NO: 16.
12. Protutijelo prema patentnom zahtjevu 11, naznačeno time što protutijelo ili njegov ulomak koji veže antigen sadrži konstantnu regiju IgG teškog lanca.
13. Farmaceutski pripravak naznačen time što sadrži protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 11 ili zahtjevu 12, zajedno s farmaceutski prihvatljivim pomoćnim sredstvom i/ili razrjeđivačem.
14. Protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 11 ili zahtjevu 12 naznačeno time što je za upotrebu u postupku smanjenja količine Aβ protofibrila kod subjekta, koji obuhvaća davanje navedenom subjektu terapeutski učinkovite količine protutijela ili njegovog ulomka koji veže antigen prema patentnom zahtjevu 11 ili zahtjevu 12.
15. Protutijelo ili njegov ulomak koji veže antigen patentnom zahtjevu 11 ili zahtjevu 12 naznačeno time što je za upotrebu u postupku liječenja Alzheimerove bolesti ili drugog poremećaja povezanog s agregacijom Aβ proteina kod subjekta koji ima navedenu bolest ili poremećaj, koji obuhvaća davanje navedenom subjektu terapeutski učinkovite količine protutijela ili njegovog ulomka koji veže antigen prema patentnom zahtjevu 11 ili zahtjevu 12.
16. Protutijelo ili njegov ulomak koji veže antigen patentnom zahtjevu 11 ili zahtjevu 12 naznačeno time što je za upotrebu u postupku liječenja Alzheimerove bolesti kod subjekta koji ima Alzheimerovu bolest, koji obuhvaća davanje navedenom subjektu terapeutski učinkovite količine protutijela ili njegovog ulomka koji veže antigen prema patentnom zahtjevu 11 ili zahtjevu 12.
17. Protutijelo ili njegov ulomak koji veže antigen patentnom zahtjevu 11 ili zahtjevu 12, naznačeno time što je za upotrebu u terapiji.
18. In vitro postupak za mjerenje količine Aβ protofibrila i/ili agregiranog Aβ proteina kod osobe, koji obuhvaća dovođenje u kontakt tkiva ili tjelesne tekućine osobe, in vitro, s protutijelom ili njegovim ulomkom koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2 i mjerenje količine protutijela ili njegovog ulomka koji veže antigen vezane za navedene Aβ protofibrile i/ili agregirani Aβ protein.
19. In vitro postupak za dijagnozu Alzheimerove bolesti kod osoba koje imaju ili su u opasnosti od razvoja bolesti, koji obuhvaća dovođenje u kontakt tkiva ili tjelesne tekućine osobe, in vitro, s protutijelom ili njegovim ulomkom koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, ili njegovim ulomkom, i mjerenje količine navedenog protutijela vezane za agregirani Aβ protein.
20. In vitro postupak za dijagnozu traumatske ozljede mozga (TBI), demencije s Lewyjevim tjelešcima (LBD), Downovog sindroma (DS), amiotrofične lateralne skleroze (ALS), frontotemporalne demencije, tauopatija, sistemske amiloidoze, ateroskleroze i Parkinsonove bolesti s demencijom (PDD) kod osoba koje imaju ili su u opasnosti od razvoja bilo koje od navedenih bolesti, koji uključuje dovođenje u kontakt tkiva ili tjelesne tekućine osobe, in vitro, s protutijelom ili njegovim ulomkom koji veže antigen prema patentnom zahtjevu 1 ili zahtjevu 2, i mjerenje količine navedenog protutijela ili njegovog ulomka koji veže antigen vezane za agregirani Aβ protein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022952P | 2014-07-10 | 2014-07-10 | |
| PCT/EP2015/065633 WO2016005466A2 (en) | 2014-07-10 | 2015-07-08 | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| EP15738876.0A EP3166970B1 (en) | 2014-07-10 | 2015-07-08 | Improved a-beta protofibril binding antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210680T1 true HRP20210680T1 (hr) | 2021-06-11 |
Family
ID=53673920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210680TT HRP20210680T1 (hr) | 2014-07-10 | 2021-04-29 | POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9573994B2 (hr) |
| EP (2) | EP3865510A3 (hr) |
| JP (1) | JP6628786B2 (hr) |
| KR (2) | KR20230129449A (hr) |
| CN (2) | CN106661103B (hr) |
| AR (1) | AR101130A1 (hr) |
| AU (1) | AU2015286707B2 (hr) |
| CA (1) | CA2951990C (hr) |
| CL (1) | CL2017000053A1 (hr) |
| CO (1) | CO2017000346A2 (hr) |
| CY (1) | CY1124563T1 (hr) |
| DK (1) | DK3166970T3 (hr) |
| ES (1) | ES2865112T3 (hr) |
| HR (1) | HRP20210680T1 (hr) |
| HU (1) | HUE053809T2 (hr) |
| IL (2) | IL282823B2 (hr) |
| JO (1) | JO3537B1 (hr) |
| LT (1) | LT3166970T (hr) |
| MA (2) | MA40224B1 (hr) |
| MX (1) | MX2017000378A (hr) |
| MY (1) | MY184890A (hr) |
| PE (1) | PE20170768A1 (hr) |
| PH (1) | PH12017500032A1 (hr) |
| PL (1) | PL3166970T3 (hr) |
| PT (1) | PT3166970T (hr) |
| RS (1) | RS61717B1 (hr) |
| RU (1) | RU2700104C2 (hr) |
| SG (1) | SG11201610734RA (hr) |
| SI (1) | SI3166970T1 (hr) |
| TW (1) | TWI678376B (hr) |
| UA (1) | UA121550C2 (hr) |
| WO (1) | WO2016005466A2 (hr) |
| ZA (1) | ZA201706272B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018522891A (ja) * | 2015-07-21 | 2018-08-16 | バイオアークティック アーベー | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
| BR112019000098A2 (pt) * | 2016-07-14 | 2019-04-09 | Bioarctic Ab | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio |
| US20200299411A9 (en) * | 2016-10-27 | 2020-09-24 | Eisai R&D Management Co., Ltd. | Composition and method for treating alzheimer's disease |
| CN111836644B (zh) * | 2018-03-08 | 2024-07-23 | 凡恩世制药(北京)有限公司 | 抗密蛋白18.2抗体及其用途 |
| EP3826674A2 (en) | 2018-07-24 | 2021-06-02 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| BR112023001061A2 (pt) | 2020-07-23 | 2023-04-04 | Othair Prothena Ltd | Anticorpos antiabeta |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| MX2024002567A (es) | 2021-08-30 | 2024-03-20 | Eisai R&D Man Co Ltd | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. |
| IL314581A (en) | 2022-02-02 | 2024-09-01 | Eisai R&D Man Co Ltd | Treatment methods using P-TAU181 LEVEL |
| CN114578066B (zh) * | 2022-05-07 | 2022-08-19 | 北京第一生物化学药业有限公司 | 检测β-淀粉样蛋白的产品和方法 |
| US12084492B2 (en) | 2023-01-20 | 2024-09-10 | Mabwell Therapeutics, Inc. | Anti-amyloid beta protofibril/oligomer antibodies and uses thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| WO1991016819A1 (en) | 1990-04-27 | 1991-11-14 | Molecular Rx., Inc. | Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein |
| US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| US6174916B1 (en) | 1990-04-27 | 2001-01-16 | Milkhaus Laboratory, Ltd. | Methods for treating herpes virus infections |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| CA2174429C (en) | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Transgenic animals harboring app allele having swedish mutation |
| WO1995031996A1 (en) | 1994-05-25 | 1995-11-30 | Milkhaus Lab | Materials and methods for treatment of plaquing diseases |
| US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
| US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性ａｐｐの定量法 |
| WO1997041856A1 (en) | 1996-05-08 | 1997-11-13 | Massachusetts Institute Of Technology | ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) |
| US20060178302A1 (en) | 1997-02-05 | 2006-08-10 | Northwestern University & The University Of Southern California | Amyloid beta protein (globular assembly and uses thereof) |
| US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| ES2253839T3 (es) | 1997-12-03 | 2006-06-01 | Neuralab, Ltd. | Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer. |
| WO2000039310A1 (en) | 1998-12-29 | 2000-07-06 | The University Of Georgia Research Foundation, Inc. | Rubredoxin fusion proteins, protein expression system and methods |
| WO2000071671A2 (en) | 1999-05-26 | 2000-11-30 | New York University | New mutant genes in familial british dementia and familial danish dementia |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| PE20010212A1 (es) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
| JP2003531570A (ja) | 1999-07-27 | 2003-10-28 | アブジェニックス インク． | 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物 |
| JP4796725B2 (ja) | 1999-08-04 | 2011-10-19 | ユニバーシティ オブ サザン カリフォルニア | アミロイドβタンパク質（球状アセンブリー及びその使用） |
| CA2388559A1 (en) | 1999-11-29 | 2001-06-07 | Neurochem Inc. | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| WO2001090182A2 (en) | 2000-05-22 | 2001-11-29 | New York University | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20030187011A1 (en) | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
| WO2003089460A1 (en) | 2002-04-19 | 2003-10-30 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
| US20040049134A1 (en) | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
| WO2004024090A2 (en) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| JP2006508072A (ja) | 2002-10-01 | 2006-03-09 | ノースウエスタン ユニバーシティ | アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用 |
| US20070099185A1 (en) | 2002-11-04 | 2007-05-03 | Bioarctic Neuroscience Ab | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
| WO2005019828A1 (en) | 2003-08-20 | 2005-03-03 | Amorfix Life Sciences Ltd. | Epitope protection assay and method for detecting protein conformations |
| EP1660533A4 (en) | 2003-09-12 | 2009-10-21 | Univ California | SPECIFIC MONOCLONAL ANTIBODIES MADE FROM PROTEINS OF DIFFERENT SEQUENCES FOR HIGHLY MOLECULAR AGGREGATIVE INTERMEDIATE PRODUCTS OF AMYLOIDS |
| SE0400707D0 (sv) | 2004-03-22 | 2004-03-22 | Bioarctic Neuroscience Ab | Transgenic animal model |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US8507206B2 (en) | 2004-07-02 | 2013-08-13 | Northwestern University | Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta) |
| US20060079447A1 (en) * | 2004-10-08 | 2006-04-13 | Wetzel Ronald B | Stabilized A-beta protofibrillar aggregates |
| WO2006047254A1 (en) | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Assemblies of oligomeric amyloid beta protein and uses thereof |
| US7780963B2 (en) * | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
| US20060240486A1 (en) * | 2004-12-15 | 2006-10-26 | Johnson-Wood Kelly L | Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
| EP1853299A4 (en) | 2005-01-14 | 2009-11-11 | Univ California | COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
| ES2340414T3 (es) | 2005-03-05 | 2010-06-02 | ABBOTT GMBH & CO. KG | Metodo de seleccion, proceso para la purificacion de oligomeros de a-beta no-difusibles, anticuerpos selectivos contra dichos oligomeros de a-beta no-difusibles y un proceso para la fabricacion de dichos anticuerpos. |
| WO2006137354A1 (ja) | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | アミロイド線維形成に対する阻害活性を有する抗体 |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| CA2626783A1 (en) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Anti-addl monoclonal antibody and use thereof |
| AU2006318537A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of Alzheimer's and related diseases |
| EP2325209A3 (en) * | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
| TW201815827A (zh) * | 2006-07-14 | 2018-05-01 | 瑞士商Ａｃ免疫公司 | 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法 |
| UA100672C2 (en) * | 2006-07-14 | 2013-01-25 | Ас Иммуне Са | HUMANIZED ANTIBODY TO b-AMYLOID PROTEIN |
| BRPI0719763A2 (pt) * | 2006-10-02 | 2014-01-28 | Ac Immune Sa | Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero. |
| JP5749009B2 (ja) * | 2007-08-13 | 2015-07-15 | バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤 |
| SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
| EP2207568B1 (en) * | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| BRPI1006448B1 (pt) | 2009-03-25 | 2021-08-17 | Genentech, Inc | Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3 |
| HUE053949T2 (hu) | 2009-06-29 | 2021-08-30 | Bioarctic Ab | N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok |
| JP5692073B2 (ja) * | 2009-08-07 | 2015-04-01 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
| WO2011104696A1 (en) * | 2010-02-26 | 2011-09-01 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| CA2806252C (en) * | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
| ES2720136T3 (es) | 2010-12-22 | 2019-07-18 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpo modificado con semivida mejorada |
-
2015
- 2015-07-08 CN CN201580036189.2A patent/CN106661103B/zh active Active
- 2015-07-08 WO PCT/EP2015/065633 patent/WO2016005466A2/en active Application Filing
- 2015-07-08 MA MA40224A patent/MA40224B1/fr unknown
- 2015-07-08 TW TW104122215A patent/TWI678376B/zh active
- 2015-07-08 JP JP2017500897A patent/JP6628786B2/ja active Active
- 2015-07-08 DK DK15738876.0T patent/DK3166970T3/da active
- 2015-07-08 SG SG11201610734RA patent/SG11201610734RA/en unknown
- 2015-07-08 MA MA053887A patent/MA53887A/fr unknown
- 2015-07-08 SI SI201531593T patent/SI3166970T1/sl unknown
- 2015-07-08 PE PE2017000024A patent/PE20170768A1/es unknown
- 2015-07-08 CN CN202011054114.6A patent/CN112390881A/zh active Pending
- 2015-07-08 LT LTEP15738876.0T patent/LT3166970T/lt unknown
- 2015-07-08 HU HUE15738876A patent/HUE053809T2/hu unknown
- 2015-07-08 KR KR1020237024350A patent/KR20230129449A/ko not_active Application Discontinuation
- 2015-07-08 AU AU2015286707A patent/AU2015286707B2/en active Active
- 2015-07-08 EP EP21154511.6A patent/EP3865510A3/en active Pending
- 2015-07-08 CA CA2951990A patent/CA2951990C/en active Active
- 2015-07-08 RS RS20210459A patent/RS61717B1/sr unknown
- 2015-07-08 PL PL15738876T patent/PL3166970T3/pl unknown
- 2015-07-08 KR KR1020167037100A patent/KR102564384B1/ko active IP Right Grant
- 2015-07-08 IL IL282823A patent/IL282823B2/en unknown
- 2015-07-08 JO JOP/2015/0167A patent/JO3537B1/ar active
- 2015-07-08 MX MX2017000378A patent/MX2017000378A/es unknown
- 2015-07-08 AR ARP150102178A patent/AR101130A1/es unknown
- 2015-07-08 RU RU2017103446A patent/RU2700104C2/ru active
- 2015-07-08 EP EP15738876.0A patent/EP3166970B1/en active Active
- 2015-07-08 MY MYPI2017700010A patent/MY184890A/en unknown
- 2015-07-08 US US14/794,172 patent/US9573994B2/en active Active
- 2015-07-08 ES ES15738876T patent/ES2865112T3/es active Active
- 2015-07-08 UA UAA201700962A patent/UA121550C2/uk unknown
- 2015-07-08 PT PT157388760T patent/PT3166970T/pt unknown
-
2017
- 2017-01-05 PH PH12017500032A patent/PH12017500032A1/en unknown
- 2017-01-09 CL CL2017000053A patent/CL2017000053A1/es unknown
- 2017-01-09 IL IL250001A patent/IL250001B/en active IP Right Grant
- 2017-01-13 CO CONC2017/0000346A patent/CO2017000346A2/es unknown
- 2017-09-15 ZA ZA2017/06272A patent/ZA201706272B/en unknown
-
2021
- 2021-04-29 HR HRP20210680TT patent/HRP20210680T1/hr unknown
- 2021-06-01 CY CY20211100477T patent/CY1124563T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210680T1 (hr) | POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| MY184154A (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| MX2021009053A (es) | Anticuerpo monoclonal recombinante para usarse en el tratamiento de la enfermedad de alzheimer. | |
| WO2010012004A3 (en) | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence | |
| RU2019118922A (ru) | Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка | |
| CY1115906T1 (el) | Ανθρωποποιημενα αντισωματα κατα του βητα αμυλοειδους | |
| MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
| JP2015530971A5 (hr) | ||
| DK2004688T3 (da) | Forbedrede selektive protofibrille antistoffer og anvendelsen deraf | |
| JP2016094424A5 (hr) | ||
| JOP20210265A1 (ar) | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| EA201492162A1 (ru) | Антитела к трансглютаминазе 2 | |
| EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| PH12021551535A1 (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| IL288894A (en) | Methods for the assessment and treatment of Alzheimer's disease and their applications | |
| EP3740761A4 (en) | ACCOMPANYING DIAGNOSTICS FOR NSAIDS AND DONEPEZIL FOR THE TREATMENT OF SPECIFIC SUBPOPULATIONS OF PATIENTS WITH ALZHEIMER'S MORBUS | |
| CY1114604T1 (el) | Ανθρωποποιημενο αντισωμα εναντιον αμυλοειδους βητα | |
| WO2022093552A8 (en) | Rev-erb agonists | |
| EA202191813A1 (ru) | Моноклональные антитела против участка бета-цепи trbv9 человека | |
| EP3854875A4 (en) | HUMAN MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO HUMAN HMGB1, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE CONTAINING SUCH HUMAN MONOCLONAL ANTIBODY | |
| MA54940A (fr) | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |